Liraglutide reverses pronounced insulin-associated weight gain, improves glycaemic control and decreases insulin dose in patients with type 2 diabetes: a 26 week, randomised clinical trial (ELEGANT).

de Wit HM, Vervoort GM, Jansen HJ, de Grauw WJ, de Galan BE, Tack CJ

Diabetologia20 Jun 2014Cited by 57 (Europe PMC)

PMID24947583DOI10.1007/s00125-014-3302-0PepBankPUB-24947583

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes and pronounced insulin-associated weight gain, adding liraglutide reduced body weight by 4.5 kg versus a 0.9 kg gain with standard therapy.
In plain wordsIn adults with type 2 diabetes who gained weight on insulin, adding liraglutide led to weight loss, while standard therapy led to weight gain.
Peptide
Liraglutide
Outcome
DecreaseBody weight change at 26 weeks
Study
n = 50
Comparator
Continued standard insulin therapy
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Studied dose
1.8 mg/day · 26 weeksAs given in this study (human).
Measurements
Body weight change
−4.5 kg
liraglutide
Body weight change
0.9 kg
standard therapy
Mean difference
−5.2 kg
liraglutide vs standard
Source sentences
Summary
Body weight decreased by 4.5 kg with liraglutide and increased by 0.9 kg with standard therapy (mean difference -5.2 kg [95% CI -6.7, -3.6 kg]; p < 0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
The primary endpoint was between-group weight difference after 26 weeks of treatment (intention to treat).
Summary · context
In a 26-week, randomised controlled trial (ELEGANT), conducted in the outpatient departments of one academic and one large non-academic teaching hospital in the Netherlands, adult patients with type 2 diabetes with ≥ 4% weight gain during short-term (≤ 16 months) insulin therapy received either open…
Report a problemFND-2494758301
02HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes and pronounced insulin-associated weight gain, adding liraglutide lowered HbA1c more than standard therapy.
In plain wordsIn adults with type 2 diabetes who gained weight on insulin, adding liraglutide lowered HbA1c more than standard therapy.
Peptide
Liraglutide
Outcome
DecreaseHbA1c change at 26 weeks
Study
n = 50
Comparator
Continued standard insulin therapy
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.8 mg/day · 26 weeksAs given in this study (human).
Measurements
HbA1c change
−0.77%
liraglutide
HbA1c change
0.01%
standard therapy
Difference
−0.74%
liraglutide vs standard
Source sentences
Summary
The respective changes in HbA1c were -0.77% (-8.4 mmol/mol) and +0.01% (+0.1 mmol/mol) (difference -0.74% [-8.1 mmol/mol]) ([95% CI -1.08%, -0.41%] [-11.8, -4.5 mmol/mol]; p < 0.001)
1 context sentence(design, population, supporting numbers)
Summary · context
In a 26-week, randomised controlled trial (ELEGANT), conducted in the outpatient departments of one academic and one large non-academic teaching hospital in the Netherlands, adult patients with type 2 diabetes with ≥ 4% weight gain during short-term (≤ 16 months) insulin therapy received either open…
Report a problemFND-2494758302
03HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes and pronounced insulin-associated weight gain, adding liraglutide reduced insulin dose, while the dose rose with standard therapy.
In plain wordsIn adults with type 2 diabetes who gained weight on insulin, adding liraglutide cut the insulin dose, while standard therapy raised it.
Peptide
Liraglutide
Outcome
DecreaseInsulin dose change at 26 weeks
Study
n = 50
Comparator
Continued standard insulin therapy
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.8 mg/day · 26 weeksAs given in this study (human).
Measurements
Insulin dose change
−29 U/day
liraglutide
Insulin dose change
5 U/day
standard therapy
Difference
−33 U/day
liraglutide vs standard
Source sentences
Summary
respective changes in insulin dose were -29 U/day and +5 U/day (difference -33 U/day [95% CI -41, -25 U/day]; p < 0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
In a 26-week, randomised controlled trial (ELEGANT), conducted in the outpatient departments of one academic and one large non-academic teaching hospital in the Netherlands, adult patients with type 2 diabetes with ≥ 4% weight gain during short-term (≤ 16 months) insulin therapy received either open…
Report a problemFND-2494758303
04HumanRandomized controlled trialSafety outcome
In adults with type 2 diabetes and pronounced insulin-associated weight gain, no severe adverse events occurred and liraglutide was well tolerated.
In plain wordsIn adults with type 2 diabetes who gained weight on insulin, liraglutide was well tolerated and no severe side effects occurred.
Peptide
Liraglutide
Outcome
No significant changeSevere adverse events
Study
n = 50
Comparator
Continued standard insulin therapy
Outcome group
Adverse events · Whole body
Studied dose
1.8 mg/day · 26 weeksAs given in this study (human).
Source sentences
Summary
Liraglutide was well tolerated; no severe adverse events
1 context sentence(design, population, supporting numbers)
Summary · context
In a 26-week, randomised controlled trial (ELEGANT), conducted in the outpatient departments of one academic and one large non-academic teaching hospital in the Netherlands, adult patients with type 2 diabetes with ≥ 4% weight gain during short-term (≤ 16 months) insulin therapy received either open…
Report a problemFND-2494758305
05HumanRandomized controlled trialSafety outcome
In adults with type 2 diabetes and pronounced insulin-associated weight gain, no severe hypoglycaemia occurred.
In plain wordsIn adults with type 2 diabetes who gained weight on insulin, no severe low blood sugar occurred.
Peptide
Liraglutide
Outcome
No significant changeSevere hypoglycaemia
Study
n = 50
Comparator
Continued standard insulin therapy
Outcome group
Adverse events · Metabolic and weight
Studied dose
1.8 mg/day · 26 weeksAs given in this study (human).
Source sentences
Summary
no severe adverse events or severe hypoglycaemia occurred.
1 context sentence(design, population, supporting numbers)
Summary · context
In a 26-week, randomised controlled trial (ELEGANT), conducted in the outpatient departments of one academic and one large non-academic teaching hospital in the Netherlands, adult patients with type 2 diabetes with ≥ 4% weight gain during short-term (≤ 16 months) insulin therapy received either open…
Report a problemFND-2494758306
06HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes and pronounced insulin-associated weight gain, insulin could be completely discontinued in five patients (19%).
In plain wordsIn adults with type 2 diabetes who gained weight on insulin, five patients (19%) could stop insulin completely.
Peptide
Liraglutide
Outcome
Not applicableInsulin completely discontinued
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.8 mg/day · 26 weeksAs given in this study (human).
Measurements
Patients with insulin discontinued
5 patients
Patients with insulin discontinued
19%
Source sentences
Summary
In five patients (19%), insulin could be completely discontinued.
1 context sentence(design, population, supporting numbers)
Summary · context
In a 26-week, randomised controlled trial (ELEGANT), conducted in the outpatient departments of one academic and one large non-academic teaching hospital in the Netherlands, adult patients with type 2 diabetes with ≥ 4% weight gain during short-term (≤ 16 months) insulin therapy received either open…
Report a problemFND-2494758304

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials2

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

2 trials · 1 ongoing · source ClinicalTrials.gov (opens in a new tab)

RecruitingPhase 3NCT06894784

A Clinical Trial to Evaluate The Effects of Semaglutide and Empagliflozin Combined to Automated Insulin Delivery on Diabetes Control in Adults Living With Type 1 Diabetes

McGill University Health Centre/Research Institute of the McGill University Health Centren = 36est. Apr 2025 to est. Jan 2027

Diabetes Type 1

Trial page ClinicalTrials.govUpdated 30 Mar 2025

Status unknownNot applicableNCT01392898

Liraglutide and Insulin Therapy in Patients With Type 2 Diabetes

Radboud University Medical Centern = 50Feb 2012 to est. May 2014

Type 2 Diabetes Mellitus

Trial page ClinicalTrials.govUpdated 2 Aug 2013

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.